Beim Braunland 1 88416 Ochsenhausen |
|
|
History
Founded in 1971, Boehringer Ingelheim Therapeutics formerly known as Labor Dr. Merk & Kollegen is based in Ochsenhausen, Germany and was a family owned company, performing R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.before being acquired by Boehringer Ingelheim in 2021.
About us
As of march 2021, Labor Dr. Merk and Kollegen GmbH became a part of the Boehringer Ingelheim family and operates under the new company name Boehringer Ingelheim Therapeutics GmbH which performs R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.
History
Founded in 1971, Boehringer Ingelheim Therapeutics formerly known as Labor Dr. Merk & Kollegen is based in Ochsenhausen, Germany and was a family owned company, performing R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.before being acquired by Boehringer Ingelheim in 2021.
About us
As of march 2021, Labor Dr. Merk and Kollegen GmbH became a part of the Boehringer Ingelheim family and operates under the new company name Boehringer Ingelheim Therapeutics GmbH which performs R&D and clinical manufacturing with a focus on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.
Facilities
With over 3600 m² state of the art laboratory capacity and a 300 m² GMP production site, our facilities encompass space for end-to-end process development, manufacturing and biosafety testing.
Quality Standards
Guaranteeing excellent quality concerning all activities is our top priority.
Facilities
With over 3600 m² state of the art laboratory capacity and a 300 m² GMP production site, our facilities encompass space for end-to-end process development, manufacturing and biosafety testing.